Today, MOG-IgG-associated encephalomyelitis (MOG-EM) is considered a separate disease entity (34).Other candidates of potential biomarkers are described in the group of cytokines [e.g., interleukin (IL)-6] (39), adhesion molecules [such as soluble intracellular and vascular cell adhesion molecule (sICAM and sVCAM) (89)], damage and repair associated molecules [like glial fibrillary acidic protein (GFAP) and haptoglobin] (39) and complement components [e.g. Complement component 1-inhibitor (C1inh), C1s, C5 and factor H] (94) (Table 3). The gene discussed is GFAP; the disease is encephalomyelitis.